SynthesisWorld journal of surgical oncology2014
Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.
Synthesis in World journal of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Superiority of the ROMA index over HE4 and CA125 for diagnosing ovarian cancer in a Bangladeshi cohort.Clinics (Sao Paulo, Brazil) · 2026Article
- Cervicovaginal lavages uncover growth factors as key biomarkers for early diagnosis and prognosis of endometrial cancer.Molecular biomedicine · 2024Article
- Endometrial Cancer Risk Among GermlineJCO precision oncology · 2023Review
- HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial Cancer: A Review.Current oncology (Toronto, Ont.) · 2022Review
- Review
- The Role of Human Epididymis Protein 4 in the Diagnosis and Prognosis of Diseases: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observational Studies.Frontiers in medicine · 2022Review
- Identification and characterization of endometrial carcinoma with tumor markers HE4 and CA125 in serum and endometrial tissue samplesJournal of the Turkish German Gynecological Association · 2021Article
- Diagnostic value of serum human epididymis protein 4 in esophageal squamous cell carcinoma.World journal of gastrointestinal oncology · 2020Article
- Meta-analysis of the prognostic role of HE4 expression in cancer patients: clinical insights into interpretation of clinical outcomes.Cancer management and research · 2019Article
- Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.Frontiers in oncology · 2018Review
- The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.Journal of clinical laboratory analysis · 2018Article
- MicroRNAs in gynecological cancers: Small molecules with big implications.Cancer letters · 2017Review
- Serum endocan levels in endometrial and ovarian cancers.Journal of clinical laboratory analysis · 2017Article
- Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.Annals of translational medicine · 2017Review
- Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study.Journal of clinical and diagnostic research : JCDR · 2017Article
- Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.Virchows Archiv : an international journal of pathology · 2017Article
- Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.OncoTargets and therapy · 2017Article
- Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer.Przeglad menopauzalny = Menopause review · 2016Article
- Molecular cues on obesity signals, tumor markers and endometrial cancer.Hormone molecular biology and clinical investigation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer (EC) is a common female malignant cancer. The age of incidence has become younger than before. If the diagnosis is during stage I, then the survival rate is about 90%. To date, there are no specific tumor markers for endometrial cancer. We usually use serum CA125 to help in diagnosing it. However, a serum biomarker CA125 greater than 35 U/ml is not useful in diagnosing EC at an early stage. Now, human epididymis protein 4 (HE4) has been intensively studied, and has been described as a new marker for ovarian cancer. The goal of this study was to evaluate the clinical value of serum HE4 in the diagnosis of endometrial cancer by meta-analysis.
methodsWe used MEDLINE, EMBASE, Cochrane Library and CBM databases to search the literature. The meta-analysis was performed by using Meta-Disc 1.4 software.
resultsAll data we obtained showed that the major advantage of HE4 lies in its specificity in endometrial cancer diagnosis. Its sensitivity in serum was not as high as expected. But this evidence is not enough.
conclusionsAdditional studies, particularly to evaluate HE4's capability in identifying EC at an early stage, will be needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.